We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Stephen Bain

Stephen C. Bain MA, MD, FRCP

Clinical Director, Diabetes Research Unit Cymru, and Medical Director for Research & Development, Swansea Bay University Health Board, Swansea University, Singleton Park, Wales, United Kingdom

Professor Bain completed his undergraduate training at St John's College, Cambridge, and then was clinically trained at King's College Hospital, London. On qualifying in 1983, he went on to hold junior appointments in London, the East Midlands, and the West Midlands, UK. His research centred on the genetics of type 1 diabetes, and he was granted a Medical Research Council Lectureship. In 1993, he became a Senior Lecturer/Honorary Consultant Physician at Birmingham Heartlands Hospital, Birmingham, with promotion to Reader in Diabetic Medicine in 1998. Professor Bain became a Fellow of the Royal College of Physicians UK in 1996. Professor Bain was appointed to a newly created Chair in Medicine (Diabetes) in the University of Wales Swansea in 2005. His clinical interests include the genetics of diabetic nephropathy, new therapies for diabetes and the provision of diabetes services within the community. He has been Chief Investigator for several multi-centre trials investigating novel therapies for diabetes.

 

Professor Bain is the Diabetes Lead Clinician for the Swansea Bay University Health Board and a member of the Wales Diabetes & Endocrine Society (WEDS) executive committee. He chairs the Joint Clinical Research Facility in Swansea and is currently Chair of the National Specialist Advisory Group (NSAG) for Diabetes in Wales.

Disclosures

Dr. Bain reports the following:

Speaker Fees: Astra-Zeneka, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Napp, Novo Nordisk, Roche, Sanofi-Aventis.

Advisory Boards: Eli Lilly, Merck Sharp & Dohme, Novo Nordisk.

Share-owner: Glycosmedia.

Expert advice: All-Wales Medicines Strategy Group & the National Institute for Health and Care Excellence (UK)